| Objective:By testing the content of adiponectin,transforming growth factor-β1(TGF-β1)and alphasmooth muscle actin(α-SMA)in serum of patients with chronic kidney disease,aiming to investigate the relationship between APN and renal fibrosis.Methods:A total of 120 inpatients diagnosed with CKD who were admitted to the Department of Nephrology of the First Hospital of Jilin University from May 2019 to March 2021 were selected as the research subjects.Meanwhile,according to the Estimated glomerular filtration rate(e GFR),the group was divided into 5 groups,with 30 cases in each group.10 patients who received physical examination in our hospital during the same period were randomly selected as the control group.The general clinical data and laboratory examination indexes of the patients were collected.Enzyme Linked Immunosorbent Assay(ELISA)was used to determine the content of APN and renal fibrosis related indexes(TGF β-1and α-SMA),and to analyze the correlation between serum APN content and renal fibrosis indexes in patients with CKD,and to explore the influence of ANP on renal fibrosis.Results:1.The levels of serum APN in healthy control group,CKD1-2,CKD3,CKD4 and CKD5 patients were 2.8(1.6,6.3)ug/ml,4.6(4.1,5.8)ug/ml,6.1(5.0,7.5)ug/ml,7.9(5.8,9.6)ug/ml,10.0(7.4,11.3)ug/ml,respectively.Compared with the healthy control group,the serum APN content in patients with CKD increased,and the difference was statistically significant(P <0.05).With the progress of CKD,the serum APN content gradually increased,and the difference was statistically significant(P < 0.05)in patients with CKD.2.The serum TGF-β1 content of healthy control group and CKD1 stage 2,CKD3,CKD4 and CKD5 patients were respectively 4.7(4.2,6.6)ng/ml,7.0(4.5,13.0)ng/ml,10.0(9.2,11.3)ng/ml,11.1(10.2,13.0)ng/ml,15.5(12.8,17.8)ng/ml.Serum levels of α-SMA were respectively 68.7(31.1,91.7)ng/L,97.09(63.9,107.4)ng/L,110.5(81.1,129.8)ng/L,122.6(102.7,170.3)ng/L,222.4(171.3,269.4)ng/L.Compared with healthy control group,serum TGF-β1 and α-SMA contents increased in CKD patients,and the difference was statistically significant(P < 0.05).With the progression of CKD,serum TGF-β1 and α-SMA contents gradually increased,and TGF-β1 and α-SMA contents in CKD5 patients were significantly higher than those in CKD1-4 patients.The difference was statistically significant(P < 0.05).3.According to the correlation analysis,the serum APN content in patients with CKD was positively correlated with the contents of TGF-β1 and α-SMA(r=0.46,0.45,P < 0.01).With the increase of serum TGF-β1 and α-SMA,the APN content showed an upward trend.4.According to the correlation analysis,the serum APN content in CKD patients was positively correlated with Scr and BUN(r=0.65,0.51,P < 0.01),and negatively correlated with e GFR(r=-0.64,P < 0.01).5.According to correlation analysis,there was a negative correlation between serum APN content and BMI in patients with CKD(r=-0.03,P < 0.04).Conclusion:1.Serum APN content in CKD patients was higher than that in healthy control group,which may be due to increased reactivity plays a protective role in the kidney.2.The content of APN in CKD patients was positively correlated with the content of TGF-β1 and α-SMA,and APN may inhibit renal fibrosis related factors through reactive increase.3.APN is expected to be a potential drug for the treatment of renal fibrosis. |
PDF Full Text Request